Index

A
abacavir (ABC), 470, 471, 534 fig., 542, 544
‘ABC’ approach prevention programme, 292
abstinence from sexual acts, 292–293, 316–317
Achmat, Zackie, 42
acyclovir, 207, 484, 522
adenovirus serotype (Ad5)-based vaccine (MRKAd5, Merck), 269, 270, 273
adolescence, 306–307
gender role norms, 308
knowledge/attitudes to HIV/AIDS, 311
risk of HIV infection, 50, 307
sexual decision-making, 317
adoption, 385
aerobic exercise, 494
African National Congress
‘Roadmap for Health Reform’ (2008), 450
agriculture, subsistence
impact of AIDS, 425
Aid for AIDS (AfA), 369
AIDS
denialism by SA government, 445–446
discrimination, 377–380
ey early cases (1981), 37–38
economic impact, 52, 417
geographic spread in South Africa, 40 fig.
health care structures, 53 (see also
primary health care system; private
health care sector; public health care
system)
impact, 51
legal assistance, 387–388 & fig.
miscategorization, 108–9
mortality/reduction of STIS incidence, 220 (see also sexually transmitted infections (STIS))
opportunistic infections, 52 (see also opportunistic infections (OIS))
stigma, 259, 261–262, 373, 376–380 (see also stigma, discrimination)
vaccines, 268–272 & fig.

AIDS Clinical Trial Group (ACTG)
zidovudine regimen 076 (1994), 394–395
AIDS memorial quilts, 374, 389–390
AIDS Restriction Genes (ARGs), 147–148
AIDS Truth Commission, 452
AIDSVAX (gp120, VaxGen) vaccine, 269
albendazole, 521
alcohol consumption, 264
abuse, 465, 541
sex workers, 332
Alexandra AIDS Orphan Project, Alexandra, Johannesburg
‘Go-go grannies’, 383
ALVAC-HIV (VCP1521, Aventis Pasteur) vaccine, 269
amoxycillin, 522
amphotericin lozenges, 522
Amplicor HIV-1 Monitor V1.5 assay (RT-PCR Roche), 112
amprenavir (AMP), 536 fig., 537, 544
anaemia, 497
anal sex, 279, 291, 299, 320, 332, 334
Ankara vaccine (MVA), 150, 270, 275
antenatal clinic surveys (ANC)
HIV incidence rates by year/province, 78–79 & fig.
HIV prevalence, 61 & fig., 573 & fig., 587 & fig.
HIV prevalence/ages, 65–68 & fig., 287 & fig.
HIV prevalence/province, 62 fig., 65 & fig.
Hlabisa health district, KwaZulu-Natal, 59, 63 fig.
national annual, anonymous, 58
antibiotics, bacterial resistance, 520
antibodies, 271, 273
antigen sandwich ELISA, 102
antigens, 133
processing/presentation, 134
‘antiretroviral anarchy’, 555
Antiretroviral Pregnancy Register, 544
antiretroviral therapy (ART), 52–53, 423, 529
adherence/treatment issues, 264–265, 503, 510, 511 & fig., 532, 540–541, 547
adverse effects screening, 524
affordability, 505–506
allocation of resources, 526
anonymity at clinics, 516
changing therapy, 546–547
choices to avoid, 543
combination therapy, 479
compatible with rifampicin-based regimens (TB), 471
complications, 524
cost factor/adherence, 511–512
directly observed therapy, 509
disease management programme, 561
dose adjustments with rifamycins, 472
drug resistance, 529, 547–549
drug security, 508
drug toxicity/intolerance, 546
economic growth initiative, 423
effect on body weight/composition, 492
funding, 506
generic drugs, 53
guidelines, 529, 531, 539, 542
‘hit early-hit hard’ philosophy, 531, 539
HIV transmission in sero-discordant couples, 280
identifying patients, 541
impact on mortality, 436, 442
initiation of treatment guidelines, 539–540 & fig., 539–543 & fig.
integrated therapy for MTB/HIV co-infection, 470
leakage/stockout of drugs, 515, 559
lifestyle modification counselling, 507
limitations, 531
metabolic toxicity, 531–532
mother-to-child transmission (PMTCT), 207–213 & fig. (see also mother-to-child transmission (PMTCT))
MTB/HIV co-infection, 467–468
nurse practitioners, 508
poverty/adherence to treatment, 512
pre-exposure prophylaxis, 280
protected/unprotected sexual behaviour, 254–255
responses to therapy, 110
simultaneous mother/child treatment, 516
training programmes for professionals, 510
transmission risk behaviours, 253–254
treatment failure, 547
treatment objectives, 531
triple combination therapy, 505, 511, 530, 543
antiseptic mouthwash, 522
apartheid ideology, 296–297
APOBec family of cellular cytidine deaminases, 148
AprimaxR HIV RNA test, 107
aqueous cream, 522
arginine, 494
asthenia, 534
asthma, 507
atazanavir (Reyataz), 533, 536, 537, 547
atypical infiltrates, 523
azithromycin, 353, 554
bacteriaemia, 480, 485 & fig., 520
bacterial antibiotic resistance, 520
bacterial infections, 463
bacterial pneumonia, 480
bacterial vaginosis, 218, 219 & fig., 220 & fig.
Barre-Sinoussi, F
isolation of HIV, 38
B-cells, 129
BED-CEIA screening test, 76
benzoyl peroxide, 522
betacarotene, 495–496, 498
bilirubin, unconjugated, 537
blood circulation/lymphatic circulation, 130 & fig.
blood donors
Club 23, 233
education/exclusion policy, 229
informed consent for HIV test, 238
self-exclusion questionnaire, 229 & fig., 233, 234
outcome, 232 & fig.
blood supply, 49
ALARP (as low as reasonably possible) principle, 234
risk factor, 234, 235 & fig.
screening for HIV-antibodies, 234
window period of infectivity, 226–228 & fig., 234–235
blood transfusion
informed consent by patient, 237
‘product liability’ of Service/doctor, 236–237
recipients infection with AIDS, 39
body cell mass (BCM), 491
Boston University School of Public Health.
Centre for International Health
AIDS costs
to businesses, 425 fig.
on commercial agriculture, 426
Botswana
antiretroviral therapy adherence, 511–512
MASA treatment programme, 513
branched DNA (bDNA, Bayer) assay, 110, 112
breastfeeding
antiretroviral trials, 209 fig.
HIV-1 transmission, 204–207 & fig., 212 & fig.
British HIV Association (BHIVA), 539, 542
Bureau for Economic Research (BER), Stellenbosch
impact of HIV/AIDS, 421–422
Bushbuckridge area, Mpumulanga, 437
C
caesarean section, 204, 212
canary pox vector vaccine (ALVAC HIV), 269–270
\textit{Candida albicans}, 519
\textit{Candida krusei}, 482, 484
Candida oesophagitis, 484 fig.
candidiasis, oral, 481 fig., 482, 526
capsid protein (p24), 88 & fig.
cardiac failure, 507
Carletonville, Gauteng, 351–352
age/gender differences, 69 & fig.
HIV incidence rates, 81–82 & fig.
HIV/STI prevalence survey, 60
peer education programme, 339
sex workers, 333

treatment for STIS, 353
Cavidi Tech ExaVir load reverse transcriptase assay, 114
CCR5 (coreceptor), 91–92, 143–144
CD-127 (IL-7 receptor), 138, 143
CD8+ CTL, 140
CD4+ T-cells, 89, 92–4 & fig., 111, 132 & fig., 135, 140, 271, 291, 531
CD8+ T-cells, 91, 111, 129, 132 & fig., 135, 142–143, 271
CD4+ T-helper cells, 140
CD4+ T lymphocyte, 481

central Memory T-cells (TCM), 138
Centre for AIDS Development
condom use, 514
cerebrospinal fluid (CSF), 519, 523
cetomacrogol, 522
chancroid, 218, 220–221
chemoprophylaxis, 479, 482
compatible regimens, 467
primary/secondary, 484
resistance to antimicrobial agents, 482
triple therapy, 505, 530
chickenpox, 487
child care committees, 384
child prostitution, 376
child-headed households, 374, 375
community/social support, 383–386
children
guardianship, 381
infectious diseases/HIV impact, 365–366
malnutrition/HIV infection, 365
micronutrient deficiencies/supplementation, 497, 498
mortality/HIV infection, 202, 363–365
rape, 163
support for HIV/AIDS families, 381
support from community workers/social services, 381
chimpanzees, 117–118, 122
chlamydia, 218, 219 fig.~220 fig., 222, 336 & fig.
chlorhexidine, 522
chronic infections, 138
circulating recombinant forms (CRFs), 118–121 & fig.
circumcision, male, 74, 75, 77, 268, 281, 576
clopidogrel, 137
clofibrate, 522
cluster foster care, 384
CM see cryptococcal meningitis
COBAS AmpliPrep/COBAS Taqman HIV-1 test, 113
coccidian parasites, 521
Commission on Macroeconomics and Health (2001)
health investment produces growth, 427
common gamma chain cytokines, 142–143
community competence/participation, 166, 381
community HIV clinics, 506–507
proposed services, 507 (see also public health care system)
594 community involvement
lay counsellors, 503
community organisation model
creating ‘critical consciousness’, 166–167
HIV infection prevention project, 166–167
community organisations
care/support for family of HIV/AIDS
patient, 380, 388 fig.
care/support of orphans, 383–386
combating stigma/discrimination of HIV/
AIDS, 378–380
HIV prevention interventions, 169–174, 259
youth participation/membership, 319
complementary health care sector, 564
condoms, 48, 183–184
accessibility, 162, 194–195, 324
efficacy, 184–186 & fig.
female, 186, 188–189, 293, 294
history/construction, 184
male, 185–187 & fig., 293
with microbicide studies/trials, 279
public sector distribution, 187–189 & fig., 588
school-based distribution, 195–196
social marketing, 190–191
technological improvements, 196–198 & fig.
contraceptive use, 315
corticosteroid ointment, 521, 523
corticosteroids, 468
Côte d’Ivoire, 491
sexual risk behaviour, 254
cotrimoxazole, 463, 482, 485, 519, 521, 523
coughs, 462
Council of International Organizations of
Medical Science (CIOMS)
revised guidelines on biomedical human
research (2002), 400, 410
crack cocaine, 240
cross-presentation, 135 &f
cryptococcal meningitis (CM), 484 & fig., 519,
523, 546
cryptococcosis, 463, 480, 517
Cryptococcus neoformans, 519
cryptosporidiosis, 480, 484 fig., 546
Cryptosporidium, 521
CSF see cerebrospinal fluid
cultural norms see sociocultural norms and
values
CXCR4 (coreceptor), 91
Cyclospora, 521
cysteine, 495
cytochrome P450-3a system, 470
cytokines, 132, 133 & fig., 142–143
cytomegalovirus, 480, 482
treatment, 546
cytomegalovirus pneumonia, 365
cytotoxic T lymphocytes (CTL), 93, 144–145,
270–271, 273
D
dagga (marijuana), 334
dapsone, 485
darunavir (Prezista), 537
Declaration of Helsinki on Ethical Principles
for Medical Research Involving Human
Subjects
‘standard of care’ provisions, 394
Declaration of Helsinki on Ethical Principles
for Medical Research Involving Human
Subjects (2008 revised)
placebo controlled trials, 403
delavirdine, 544
Demographic and Health Survey (1998, 2003;
SADHS), 158, 191, 192, 300
dendritic cells (DCs), 130–131 & fig., 134, 137
depression, 262, 264, 541
dermatophyte (fungal) infections, 522
developing countries
placebo controlled medical trials, 394–398
diabetes, 507
diabetes mellitus, 492
diabetes mellitus, frank, 532
diabetes type 1, 136
diagnostic technology, 76, 97–101, 103–104,
106–9
centralised laboratory/peripheral site
assays debate, 114
false-positive results, 105–106
quality of test results, 114
selecting type of test, 103–104
dialysis, 526
diaphragm use, 198
diarrhoea, 497
chronic, 362 fig., 480, 503, 521, 525
chronic, pathogen-negative, 481 fig.
impact of vitamin A, 496
didanosine (ddl), 533, 534 fig., 543–544, 546,
549
dietary counselling, 493
Diffusion of Innovations theory, 170–171
discordant sexual acts
HIV prevention measures, 292–302
discrimination
against HIV-positive people, 377
Dlamini, Gugu, 377
donovanosis, 220
DOTS (Directly Observed Therapy, Short Course) strategy, 473, 474, 503, 507, 508
doxycycline, oral, 522
DramAidE programme, 171, 323, 389
dried blood spots (DBS), 100, 104–105
drug resistance assays, 548
Du Cohort see truck-stops, KwaZulu-Natal
Dual Loyalty Working Group (DLWG)
dual technology platform (DTP), 111

E
economics and AIDS epidemic, 418–424 & fig.
education, 319
efavirenz (EFV), 469, 470, 471, 524, 544, 549
Effector Memory T-cells (TEM), 138
antigen sandwich, 102
antigen, 102
ELISPOT assay, 150
evitalegravir (GS 9137), 538
empowerment, 166
emtricitabine, 534 fig., 545
endemic mycosis, disseminated, 480
enfuvirtide (ENF, Fuzeon, T20), 90, 538
enteropathogenic bacteria, 463
entry inhibitors, 87, 90, 92
epidermis, 143
env protein (Env), 88, 90, 273
Enzyme Linked Immunospot (ELISPOT) assay, 150–151, 271
esoinophilia, 524
epilepsy, 507
epitopes, 133–134, 137, 147
escort agencies, 330, 332
Essential Medicines List see South Africa. Department of Health
ethics
medical research trials, 394–406
placebo controlled medical trials, 394–398
researcher/clinician role conflict, 407–410
sexionality, 296–297
etravirine (Intelence, TMC 125), 538
extensively drug resistant tuberculosis (XDR-tuberculosis), 464

F
facial rashes, 522
family
economic impact of AIDS, 417–418
impact of HIV/AIDS, 373–376
Fas-FasL (ligand) interaction, 132
femininity, 294–296, 301
flow cytometry analysis, 111
fluconazole, 523
fluconazole therapy, 520
food hygiene, 483
food security, 490
fosamprenavir, 537
foster care, 384
Free State province antiretroviral therapy moratorium, 451
fungus infections, 503
fungus, 122
Fusin, 91

G
gastroenteritis, 365
gastrointestinal tract (GALT), 143
disease, 490, 534
gender role norms, 324
determinant of HIV risk/vulnerability, 308, 324
generics, 555, 557
Gilbert’s trait, 537
Gila’s trait, 537
Gingivitis, 522
Global Fund against AIDS, Tuberculosis and Malaria (WHO), 557, 589
glucoronylation enzyme genotype (Gilbert’s trait), 537
-glucuronidation metabolic, 531–532
glutamine, 493
glutathione (GSH), 495
-glutathione peroxidase (GSHPX), 495
glycoprotein viral envelope (gp), 87–88
glycosylation, 273
gonorrhoea, 218, 219 fig.–220 fig., 222, 335–336 & fig., 349
gorillas, 122
G-protein-coupled receptor(s), 91
granulomatous inflammatory response, 523
oxidative stress, 495
political responses to epidemic, 52
population dynamics model, 56 & fig.
population-based surveys, 60
positive prevention interventions,
252–266 & fig., 255–259 & fig., 305–306,
320–324, 353–354
prevalence, 56–58 & fig., 70 & fig., 309–310
& fig.
prevention strategies, 41, 48–49, 169, 198,
268, 588, 590
primary HIV infection (PHI), 106–9
progression patterns, 94–5 & fig.
quality of life, 522
racial differences, 70 & fig.
regulatory/accessory proteins, 89
re-infection/resistant virus, 515
screening tests, 97
seroconcordant relationships, 252–253,
262
seronegativity, 144–145, 333
sexual coercion, 325
skin problems, 503
status disclosure, 262–263
empowerment issue, 263
STIs as co-factor for transmission,
217–218, 263–264
transmission
biological mechanisms, 291–292 & fig.
by blood transfusion, 233–236
positive prevention, 250–253
sexual, 91, 93
see also sexual behaviour; sexual risk
behaviour
transmission risk behaviours, 49, 250,
262, 297, 300–301
treatment resistant variants, 254
triple therapy, 505, 530
vaccinations, 481, 486
vaccines, 87, 106, 124–125, 127–128,
147–149, 268–272 & fig.
STEP HIV vaccine trials network
(HVTN)/Merck Ad5, 149–150
viral diversity immune-driven, 141
viral replication, 89–90 & fig.
viral structure, 47
voluntary counselling/testing (VCT), 251,
256, 261–262, 280, 325, 451, 507, 542,
588
HIV-1 infection
immune responses and, 139
T-cell response, 140
HIV-1 M group, 118, 120
HIV-1 non-B subtypes, 114
HIV p24 antigen test, 102, 107
HIV positive status
positive transmission risk prevention
interventions, 255–261 & fig.
sexual practices, 252–253
HIV-1 subtype B, 123
HIV-1 subtype C, 61, 91, 117, 123
HIV-1 type
gene flow, 88 fig.
replication cycle, 89
three lineages (M, N, O groups), 117–118
& fig.
HIV-2 type
three lineages (A, B, G groups), 117–118
& fig.
HIV-2 type infection
choice of antiretroviral therapy, 544
HIV/AIDS
aggressive management of STIS, 263
gender-sensitive programmes, 302
mental health problems, 264
role play to practice disclosure, 263
status disclosure decision, 263
HIV/AIDS myths, 311, 315
African beliefs, 512
‘virgin cleansing’, 163
HIV/AIDS Prevention Research Synthesis
study, 169
HIVNET 012 regimen, 207, 210
HIV-uninfected, 91
hospital admissions problems, 363
rise in mortality/hospital overcrowding,
367
Hlabisa district, KwaZulu-Natal
antenatal clinic surveys (ANC), 59, 66 & fig.
HIV incidence rates in ANC data, 79–80
& fig.
hospital bed occupancy, 361–362
overcrowding/‘rationing’ of health care, 367
population, 345–346 & fig.
TB caseload/antenatal HIV prevalence, 71
& fig.
Hogan, B, 43, 450–451
home-based care programmes (HBC), 526
homosexuals, 123
diagnosed with AIDS, 39
household economic impact assessments,
428–429
impoverishment due to AIDS, 429
598

HSV-2 seroprevalence, 220
human herpes virus 8, 483
see also herpes simplex virus type 2 (HSV-2)
Human Development Index (HDI), 419
human leukocyte antigens (HLA), 136–137, 145–146
significance in vaccine design, 146
human papillomavirus, 220
Human Sciences Research Council national population-based survey report, 60, 70
Human T leukemia virus types 1 & 2 (HTLV-1 & HTLV-2), 38
humoral (antibody-mediated) immunity, 271
hunger, 512
hyperbilirubinaemia, 544
hyperlipidaemia, 492, 532, 535
hypertension, 507
hypoxia, 519

I
ichthyosis (dry skin), 522
ICS assay, 151
'Image' prevention project, Limpopo province, 157–158, 171, 176–178
immune reconstitution/restoration inflammatory syndrome (IRIS), 468, 480, 522–523, 546
disorders, 467, 469
see also paradoxical reactions
immune responses, 128–129, 531
acquired, 128
cellular, 270–271
humoral, 271–273
innate, 128
mucosal, 274
prime-boost strategy, 274
immune system anatomy, 129–132 & fig., 129–133 & fig.
immunisation, 479
immunogenicity of vaccine, 150
incidence rates of infection, 74–76
cohort studies, 75
mathematical/statistical estimating methods, 75–76
India ink stain, 519
indinavir (IDV), 536 fig., 537, 542, 544
Indonesia
supplementation trial, 497
infants
HIV diagnostic testing, 97, 100, 109–110
influenza vaccination, 487
information technology resources, 559
ING Barings
impact of AIDS, 421
insect bites, 521
Institute for Democracy (IDASA)
AIDS impact on investment, 423
insulin resistance, 532, 535
integrase enzymes, 89–90
interferon-alpha, 545
Interleukin-2 (IL-2), 38
International AIDS Conference, Durban (2000), 42, 585
International Conference on Harmonisation, 557
International Union Against Tuberculosis and Lung Disease, 464
interventions
design, 321–324
versus programmes, 320–321
targeting structural causes of HIV/AIDS, 324, 353–354
Intracytoplasmic Cytokine (ICC) assay, 271
intravenous drug use (IVDU), 49, 243–245 & fig., 496, 541, 588
choice of antiretroviral therapy, 545–546
heroin, 243–244
HIV/hepatitis transmission, 246
information about risks, 247
needle exchange programmes, 246–248
needle sharing, 245–246, 292
investments
impact of HIV/AIDS, 422
iron deficiency, 497
iron deficiency/supplementation, 497, 498
isoniazid therapy, 465–466, 472
Isospor, 521
isosporiasis, 480, 484 fig., 485 fig.
itraconazole, 522

J
Janus kinase/signal transducers and activators of transcription (JAK/STAT), 143
Joint Civil Society Monitoring Forum (JCSMF), 445
junior doctors
palliative therapy issues, 525
public/private partnerships, 524

K
takesra, 549
Kaposi’s sarcoma, 483, 517, 526, 546

HIV/AIDS in South Africa
Kenya
sexual risk behaviour, 254
Kericho District, Kenya
AIDS impact on productivity, 426
Khomani campaign, 323
*Klebsiella pneumoniae*
multidrug resistance, 520
KwaZulu-Natal
age/gender differences, 68–69 & fig.
genre stereotypes/cultural norms, 295–296
microbicide trial with sex workers, 76–77 & fig.
sex workers/clients, 60
virgin testing, 300

**L**
labour
effects of HIV/AIDS, 423
lactic acidosis, 524, 543–544
lamivudine, 471, 534 fig., 542, 544, 545, 549
*Lancet Series on Health in South Africa* (August, 2009), 453
latent tuberculosis infection, 464–465, 473
lay counsellors
HIV wellness programmes, 507
lcx HIV RNA Quantitative Assay (Abbott Diagnostics), 110
leukoplakia, oral hairy, 481 fig., 526.
life expectancy (EO), 433
at birth, 427
life skills programme, 323, 378
lipid peroxidation, 495
lipodystrophy syndrome, 489, 492, 532, 535
liver disease, 465
long-term non-progressors (LTNP), 94–5 & fig., 146–147
lopinavir (LPV), 470, 471, 536, 544, 547
LoveLife campaign, 323, 325
lung disease
smoking-related, 507
lymph nodes, 129–130
lymphadenopathy, 523
lymphadenopathy-associated virus (LAV), 38, 362, 468
lymphocytic interstitial pneumonitis, 517
*Lymphogranuloma venereum*, 220
lymphoma, 546

**M**
macroeconomics
impact of AIDS, 420–424 & fig.
maculopapular rash, 485
Madlala-Routledge, N, 43, 448–449
maize-based supplements, fortified, 493, 499
major histocompatibility complex (MHC), 136
malaria, 480
pregnant women, 483, 486
vector control, 483, 486
Malaria Control Programme (1990-1992), 59
Malawi
HIV prevalence, 57 & fig.
malnutrition, 489–491
Mandrax (methaqualone), 242
Maputo Statement on HIV and AIDS in Southern Africa (1990), 41
maraviroc (Selzentry), 90, 538
Masaka study, Uganda, 222
masculinity, 294–296, 301
mastitis, subclinical, 498
mathematical models, 569–583 & fig.
disease processes/dynamics, 54
effectiveness of vaccination/drug programmes, 125
Gupta model, 302–303
high viral load/HIV transmission risk, 280
HIV associated health care costs, 366–367 & fig.
HIV transmission risk, 256
HIV/AIDS in adults, 573 & fig.
HIV/STI interaction, 223
incidence estimates, 75
integrated support of families/children affected by HIV/AIDS, 388 fig.
mines’ single-sex hostels, 353
natural history of HIV/AIDS, 571
residual risk of blood, 235
sex ratio of HIV prevalence, 298, 574–575
South African AIDS epidemic, 265
typography, 571
matrix protein (p17), 88 & fig.
Mbeki, Thabo, President
antiretroviral therapy controversy, 42, 445–450
HIV/AIDS myths, 513, 586
meat, adequately cooked, 483
Médecins Sans Frontières, Khayelitsha, 42, 509, 514, 587
media advocacy theory, 168
medical aid schemes
antiretroviral therapy, 555
see also private health care sector
medical practitioners
HIV/AIDS: dual loyalty conflicts, 407–414
irrational/unreasonable state health policies, 410–412
medical research
placebo controlled trials, 394–406
researcher/clinician role conflict, 407–410
medicine management cycle
distribution, 559–560
procurement, 556–558
selection, 552–556
use, 561–564
medicines
quality control, 558
Medicines Control Council (MCC), 557
Good Manufacturing Process inspections, 558
Médicins Sans Frontières, Khayelitsha
antiretroviral therapy provision, 509, 587–588
mefloquine, 486
MEMA kwa Vijana study, Mwanza, Tanzania, 171–172, 173
see also Mwanza district, Tanzania
Memory Box Project, 373, 388–389
men
anaemia, 497
ANRS male circumcision trial of HIV incidence, 74, 75, 77
circumcision, 268, 281
cultural values/gender role norms, 295, 308, 317
HIV blame, 515
HIV prevalence, 574
HIV-wasting syndrome, 491–492
who have sex with men (MSM), 61, 144, 588 (see also homosexuals)
see also masculinity; sexual behaviour
Men as Partners intervention, 324
meningitis, 463
see also cryptococcal meningitis (CM)
mental illness, 507
methadone, 545–546
methamphetamine (‘tik’), 240, 245–246
methaqualone, 245–246
methcathinone (‘khat’), 245–246
metronidazole, 521–522
microbicides, 75–77 & fig., 76–77 & fig., 87, 92, 268, 275–276 & fig.
studies/trials, 276–278 & fig.

microfinance
combined with gender/HIV training, 176–178
micronutrients, 53, 489, 494, 498
microsporidiosis, 480, 483
Microsporidium, 521
migrants/migrant labour system, 50–51, 122, 287, 344–345 & fig.
circular migration and HIV infection, 163–164, 288, 342–343 & fig., 349–351 & fig.
HIV/AIDS: African research studies, 348
interventions for treatment/management of STIs, 352–353
mining industry, 164, 346–347
sending/receiving areas, 352
and sex workers, 331
‘types’/forms of movement, 347–348
miliary tuberculosis, 468
Millenium Development Goals (MDGS; 2000), 453
mining industry
productivity: impact of AIDS, 426
and sex workers, 333
see also Carletonville, Gauteng
mitochondrial toxicity, 532
mitogen-activated protein kinase (MAPK), 143
Mlambo-Ngcuka, P, 447–448
Modified Vaccinia Ankara (MVA) trial, 150, 270, 275
Montagnier, L
isolation of HIV, 38
morphine, 525
mortality
age distribution, 440–441 fig.
AIDS-related, 52, 71, 576 & fig.
adults, 433
children under five, 433
impact on behaviour of survivors, 373–374
infants (IMR), 432–433
causes of death, 433–435, 439 fig.
MTB/HIV co-infected patients, 463
verbal autopsies by health workers, 435
mother-to-child transmission (PMTCT), 48, 201–202, 543
antiretroviral therapy (ART), 543–544, 553
antiretroviral trials with breastfeeding/non-breastfeeding women, 208–9 fig.
diagnosis, 109–110

HIV/AIDS in South Africa
INDEX

formula milk provision/stigma, 514
gender stereotypes reinforced, 295–296
impact of vitamin A, 496
regimen 076 of zidovudine (ACTG), 213, 394–398
routes of transmission, 203 & fig.
treatment guidelines, 543–544
UN programme, 214
voluntary counselling and testing (VCT), 514, 589
Motlanthe, K, 450
Motsoaledi, A, 451
Mpondombili Project, KwaZulu-Natal, 324
MTB/HIV co-infection, 52, 71 & fig., 359, 360, 362, 437, 457–466 & fig., 508
antiretroviral therapy, 554
chemoprophylaxis, 463
compatible regimens, 467, 469
clinics: re-infection problem, 509
nutrition, 489
opportunistic infections, 463
preventive therapy, 465 & fig.
secondary preventive therapy (TB), 466
sputum testing, 516–518
standard rifampicin-based regimen, 463
treatment of TB, 525
weight loss, 491
Mwanza district, Tanzania, 221, 263, 351–352
Mycobacterium avium intracellularae, 521
Mycobacterium tuberculosis, 457, 479, 481, 509, 521, 523
N
n-acetylcysteine (NAC), 496
Nairobi, Kenya
costs of managing HIV-positive patients, 366
HEPS in sex workers, 144–146
National AIDS Convention of South Africa (NACOSA), 41
National Institutes of Health workshop (US) behaviour analysis factors, 165
National Network on Violence Against Women (NNVAW), 168
National Strategic Plan for AIDS/TB see South Africa, National Strategic Plan on HIV, AIDS and Sexually Transmitted Infections (the NSP)
National Tuberculosis Control Programme, 507

DOTS infrastructure, 473, 474, 503, 507, 509
needle exchange programmes, 240, 246–247
state intervention issue, 248
nelfinavir (NFV), 536 fig., 537, 542, 544
neuralgia, 522
neuropsychiatric events, 546
neutropenia, 485
nevirapine (NVP), 90, 195, 207, 470, 471, 524, 543–544, 549
Nigerian drug traffickers, 242–243
nocardiosis, 517
nodular acne, 522
non-nucleoside reverse transcriptase inhibitors (NNRTIS), 90, 469, 470, 522, 529, 530, 534–535 & fig.
nonsteroidal anti-inflammatories, 468
non-tuberculosis mycobacteria, disseminated, 480
non-typhoid salmonella species, 520
nosocomial transmission, 464
nuclear factor KB, 495
nucleic acid techniques (NAT), 101, 109, 230
impact on blood safety, 236
nucleoside reverse transcriptase inhibitors (NRTIs), 90, 529, 532–533 & fig.
adverse reactions, 532
triple combination regimens, 543
nucleotide reverse transcriptase inhibitors (NtRTIS), 533–535 & fig.
NucliSens HIV-1 V1.1 Assay, 113
NucliSens HIV-1 qt assay (Organon Technical), 110, 112
nurse practitioners protocols for safe/effective antiretroviral programmes, 508
nutrition as HIV infection therapy, 53
nutritional supplements, 489, 493
nystatin, 522
O
oesophageal candidiasis (OC), 362 fig., 480, 482, 484, 519
oesophageal thrush, 525
opportunistic infections (OIs), 53, 479
initiation of antiretroviral therapy, 546
prevention strategies, 480–485
timing/CD4+ counts, 481 fig.
oral candidiasis, 362, 365, 522
orphans, 72, 373, 376, 427
basic strategies of care, 382–383
community care initiatives, 383–386

P
p24 antigen test, 100, 102, 109, 114
P450 enzyme system, 535–536
Paediatric AIDS Clinical Trials Group (PACTG), 207
paediatric health care services, 359–360
morbidity/mortality of HIV infected children, 363–365 & fig.
‘rationing’ of hospital access of HIV-positive children, 368 & fig.
palliative care, 524
pancreatitis, acute, 524
paradoxical reaction, 468, 523
PAVE 100 vaccine trial, 150
peer education, 323–324, 339
pelvic inflammatory disease, 218
perforin, 132
pericardial effusions, 523
peripheral blood mononuclear cultures (PBMC), 101, 109
peripheral neuropathy, 543, 546
PETRA trial, 210
Pfizer fluconazole donation programme, 520
Phambili vaccine trial, 150
Phaphama Project trial, Cape Town
STI risk reduction counselling intervention, 170
pharmaceutical personnel, 562
placebo controlled medical trials, 394–398
Plasmodium falciparum, 463, 485
resistance to sulfadoxine-pyrimethamine, 486
pleural effusions, 523
PLHA (persons living with HIV/AIDS) support group
link for family support, 381, 388–391
pneumococcal infections
vaccination, 486
Pneumocystis jirovecii pneumonia (PCP), 365, 463, 480, 481, 484 fig., 485 fig., 519
diagnosis, 517
resistance to cotrimoxazole, 519
pneumonia, 362, 365
bacterial, 480, 484–87 fig.
polychromatic flow cytometry, 150
polymerase-chain-reaction-based assay, 530
polymerases (Pol), 89, 112
population serosurveillance, 97, 104–105
misclassified vaccine recipients, 106, 108–9
post-TB bronchiectasis, 517
post-traumatic stress, 264
poverty, 324, 504
and adherence to ART, 512
influence on sexual behaviour, 164, 287, 418
poverty eradication strategy, 489, 499
prednisone, 468, 519
prednisone, oral, 523
pregnancy
iron-deficiency anaemia, 497
malaria prevention, 486
subclinical mastitis, 498
vitamin supplementation, 498
see also antenatal clinic (ANC) surveys; mother-to-child transmission (PMTCT)
President’s Emergency Plan for AIDS Relief (PEPFAR), 589
primary health care sector, 503
HIV infected patients, 506–507
nurse practitioners, 508
primary health care system, 53
medication availability/suitability, 522
rational use/referral policies, 368
primates, 118, 120
private health care sector, 368–369, 541
antiretroviral therapy, 555
economic burden of AIDS, 369–370
funding, 504
managed care programmes, 369
measures to transfer AIDS burden, 369–370
out-sourced laboratory functions, 558
quality assurance, 563
Procleix Ultrio specimens, 107
product liability, 236
Project Respect trial (US)
HIV risk reduction intervention, 169
protease enzyme, 87, 89, 530
protease inhibitors (PIs), 90, 469, 496, 529, 530, 535–536 & fig.
boosted, 536–537
prurigo, 521
pruritic papular eruption (PPE), 521, 523
public health care system, 53, 504
acute/chronic care services, 507
antiretroviral therapy, 561–564, 587
choice, 549
attitude to youth/adolescents, 318–319, 325
choice of antiretroviral therapy, 549

© in this web service Cambridge University Press

www.cambridge.org
cost of HIV-positive patient care, 366–367 & fig.
diagnostic dilemmas, 526
Essential Drug List, 527, 554
funding, 504
HIV uninfected, 363, 367
hospital admissions policies, 363, 526
impact of HIV/AIDS, 359–361 & fig., 421, 426
information technology resources, 559
junior doctors, 524
limited capacity, 509
medicines selection system, 554–555
procurement, 556–558
overcrowding, 367
patient records, 559
pharmaceutical depot quality assurance, 558
professional development/education, 527
quality assurance, 563
resource allocation, 526, 540
theft/stock-outs, 559
productivity: impact of AIDS, 426
PVP, 523
pyrazinamide, 465
quality assessment, 115
quality assurance, 114–115
quality control, 115
quality of life, 521–522
racist ideology, 164, 296–297
Rakai study, Uganda, 221–222, 254, 351–352
raltegravir (Isentress, MK-0518), 90, 538
randomised controlled trials, 223, 481, 485
rape
post-exposure prophylaxis (PEP), 514
reactive oxygen intermediates (ROS), 495
RealTime HIV-1 Assay (Abbott Laboratories), 113
rechallenge/desensitisation, 485
recombinant human growth hormone, 492–493
refugees, 347–348
research and development
clinical trials in developing countries: ethical issues, 52
respiratory tract infection
antibiotic treatment, 520
resting energy expenditure (REE), 491
Retroviridae family
primate-infecting lentiviruses, 117, 118
reverse transcriptase enzyme (RT), 87, 88 & fig., 89–90
rhesus macaque monkeys, 124, 145, 274
rheumatoid arthritis, 136
ribavirin, 545
rifabutin, 470
rifampicin therapy, 463–466, 469
rilpivirine (TMC278), 538
ritonavir (RTV), 470, 471, 533, 536 & fig., 537, 542, 544, 547
RNA polymerases
non-immune host factors role, 148
RNA viral load test, 99, 101, 107, 110–111
Roche AmpliScreen specimens, 107
RT-PCR assay (Roche), 110, 112
Salmonella bacteraemia, 483, 484 fig.
Salmonella species, 485, 485
saquinavir (SQV), 470, 471, 536 & fig., 542, 544
scabies, 521
schools, 319, 325
dropouts, 376
institutional climate’s effect on risk behaviour, 162
life skills programme, 323
peer integration of orphans/HIV-positive children, 381
seborrhoeic dermatitis, 522
Senegal
antiretroviral therapy, 512
HIV infection/seasonal migration, 349
serologic testing algorithm for recent HIV seroconversion (STARHS), 107
Sex Worker Education and Advocacy Task Group (SWEAT), 339
sex workers, 76, 329–333 & fig.
anal sex practice, 299
Col-1492 phase III multicentre microbicide trial, 74, 75, 76–77
disempowerment, 338
and drug trafficking/use, 242–243, 332
highly exposed seronegatives (HEPS), 144–145
HIV/STI prevalence, 330–331 & fig., 335–336 & fig., 339
KwaZulu-Natal, 299
near mining industry, 353
racial differences, 332
sexual behaviour, 515
adolescents, 311
age difference between partners, 298
age of sexual debut, 158 fig., 297, 311–313, 316–317 & fig.
douching/intra-vaginal substance use, 335
‘dry sex’ practices, 335
gender constructs, 163–164, 286, 308
HIV resistant virus, 510
multiple partners, 159 & fig.
networking patterns, 313–315 & fig.
safe, 483
safer sex interventions, 515
secondary abstinence, 159
self-reporting reliability, 173
sexual power
unequal distribution between men/women, 297
sexual risk behaviour, 48, 157
associated with antiretroviral treatment, 255, 588
discordant sexual acts, 292–293
effect of institutional climate of health services/schools, 162
gender-related determinants, 301
HIV positive prevention interventions, 255–259 & fig.
HIV prevention interventions, 169–179, 292–303, 589
influencing factors
distal context, 163–164, 169, 171–172
personal, 161
proximal context, 161–162, 169, 170–171
multiple concurrent partners, 301
positive prevention interventions, 255–259 & fig.
vioence, 299, 318
sexually transmitted infections (STIS), 49, 184–186, 216–217
aggressive management for HIV/AIDS people, 263–264, 589
coonfection of HIV positive people, 252
effect of HIV on incidence of STIS, 218, 254 & fig.
HIV transmission enhanced, 216, 254 & fig., 288–291 & fig.
in pregnant women, 291
presumptive treatment, 222–223
prevalence, 219–221 & fig.
services to sex workers, 339–340
syndromic management, 221
treatment/effect on HIV incidence, 221–224
Shilowa, M, 451–452
shingles, 522
simian immunodeficiency viruses (SIV), 117–118
Simple/Rapid assays, 97–98
rapid test kits, 103
Sindbis vector, 270
single-parent households
headed by grandparent, 375
headed by women, 375
‘skipped generation’ households, 374–375
single-platform technology (SPT), 111
Sisters-for-Life programme, 176–178
skin necrosis (Stevens-Johnson syndrome), 524
skin rashes, 521–522, 524, 535
‘skipped generation’ households, 374–375
‘slim’ disease, 362, 490
smear-negative tuberculosis (SNTB)
simple case definitions for diagnosis, 517, 518 & fig.
social capital theory, 167–168
social cooperation, 428
social franchising of youth interventions, 323
social marginalisation
influence on sexual behaviour, 164
sociocultural norms and values, 319–320
gender roles/responsibilities, 302, 308
masculinity/femininity, 294–296
sooty mangabey monkeys, 122
Soul City Institute for Health and Development Communication, 168, 323
South Africa
AIDS impact, 424
AIDS policy (1994–1999), 41–42
AIDS policy (2004–2008), 43
District Health Information System, 560
Domestic Violence Act, 168
Medical Schemes Act (1988), 369
Medicines Act, 557
National Drug Policy (1996), 562
National Strategic Plan on HIV, AIDS and Sexually Transmitted Infections (2007-2011, ’the NSP’), 43, 448, 453, 553, 554, 587 & fig.
Operational Plan on the Comprehensive Management, Care and Treatment of HIV and AIDS (2003), 445
production sectors/economic activity (2007), 424 fig.
Standard Treatment Guidelines (STGs) for Primary Health Care (1996; 1998; 2008), 552, 553
South Africa. Constitutional Court ruling on provision of nevirapine by government, 586
Guidelines for Good Practice in the Conduct of Clinical Trials in Human participants in South Africa (Good Clinical Practice or GCP; 2000), 398
Guidelines for Good Practice in the Conduct of Clinical Trials in Human participants in South Africa (Good Clinical Practice or GCP; 2006 revised), 402
national antiretroviral treatment programme (2003), 445–447
National Health Act (2004), 227
National Strategic Plan for HIV prevention (2007), 252
Policy to Protect the Safety of the Blood Supply against the HIV/AIDS Pandemic (2000), 227, 236
Policy with regard to Blood Transfusion in South Africa (1998), 227, 236
prevalence of HIV infection in women: annual surveillance, 54
Regulations regarding Blood and Blood Products, 227, 236
Standards for the Practice of Blood Transfusion in South Africa, 227, 236
South Africa. Department of Social Development
Community-Driven Model for integrated support of families/children affected by HIV and AIDS, 388 fig.
Social assistance and social welfare services, 385
Social development or poverty relief programme, 385
South Africa. Interim National Health Research Ethics Committee

Ethics in Health Research: Principles, Structures and Processes (EHR; 2004), 401–402
South Africa. National Treatment Plan, 505, 516
Rural Development Plan, 510
South Africa. National Tuberculosis Control Programme see National Tuberculosis Control Programme
South African AIDS Vaccine Initiative (SAAVI), 150, 275
South African Community Epidemiological Network on Drug Use (SACENDU), 241
South African Intrapartum Nevirapine Trial (SAINT), 210
South African Medical Journal
first AIDS report (1983), 39
South African Medical Research Council (MRC) mortality pattern report (2001), 435–436 & fig.
South African Medical Research Council (MRC). Burden of Disease Research Unit ASSA2000 models, 437–442 & fig.
South African National Accreditation System, 227
South African National AIDS Council (SANAC), 43, 448, 589
South African National Blood Service (SANBS), 227
Blood Safety Policy, 227
Clinical Guidelines on the appropriate Use of Blood, 238
mission statement, 228
South African National Tuberculosis Control Programme, 473, 503, 507
Southern African HIV Clinicians’ Society, 504
guidelines for ART (2002), 539, 542
preferential pricing arrangements, 556
triple therapy initiative, 505, 530
spondalysing ankylosis, 136
sputum culture, 463
sputum testing, 508
Staphylococcus aureus methicillin-resistant, 520
Starting Antiretroviral therapy in three Points in Tuberculosis treatment (SAPIT) trial (2009), 470
statistics
stavudine, 471, 534, 534 fig., 543, 544, 549, 553
STEP HIV vaccine trials network (hvtn)/Merck Ad5 vaccine trial, 149–150
'Stepping Stones' prevention project, Eastern Cape province, 157–158, 167, 171, 179, 324
steroid cream, 522
Stevens-Johnson syndrome, 524
stigma/discrimination against HIV/AIDS, 514, 588
antiretroviral therapy adherence affected, 514
interventions to reduce, 378–379
street children, 376
Streptococcus pneumoniae, 463, 482
penicillin-resistant, 520
subsistence farming
AIDS impact: Zimbabwe, 425
'sugars', 242
sulfadoxine-pyrimethamine (Fansidar), 486
surrogate parent model, 384
syphilis, 218–220 fig., 221, 222, 335–336 & fig., 349
T
T lymphocytes, 497
Tanzania, 256
T-cell receptors (TCRs), 133–136 & fig., 137
T-cells, 129–131 & fig.
memory phase, 138
see also Central Memory T-cells (TCM), Effector Memory T-cells (TEM)
Teaching Men to Care intervention, 324
teenage pregnancy, 298, 310–311
tenofovir (Viread), 534 fig., 544, 545, 553
gel, 277–278 & fig., 470
oral formulation, 280, 533
terbinafine, 522
Thai RV144 vaccine trial, 269, 273, 274
Thailand
100% Condom Programme, 172, 294, 339
condom use, 570
PHPT2 trial, 207
Thandanani Children’s Foundation. Development Programme, Msunduzi Municipality, 385
thymulin, 497
thymus gland, 129, 531
‘tik’ (methamphetamine), 240, 245–246
tipranavir (Aptivus), 537
Toxoplasma gondii, 463, 483, 484
toxoplasmosis, 480, 482, 483, 484 fig., 485 fig.
traditional healers, 259
cooperating with allogentic practitioners, 513, 564
HIV/AIDS care, 512
informal condom distribution, 195–196
Treatment Action Campaign (TAC), 42, 445
trichomoniases, 218, 219 fig.–220 fig., 336 & fig.
triglycerides, medium-chain, 493
trimethoprim-sulfamethoxazole (cotrimoxazole) see cotrimoxazole
triple combination therapy, 505, 511, 530
trizivir, 470
truck-stops, KwaZulu-Natal
anal sex practice, 299
safe sex practices, 336 & fig.
truck driver HIV prevalence, 337 & fig.
Truvada (tenofovir + FTC)
oral formulation, 280
Tshabalala-Msimang, M
antiretroviral controversy, 42–43, 445–450
HIV/AIDS myths, 513
tuberculinskin test (TST), 464, 486
tuberculosis (TB), 362 fig., 480, 503, 507
associated with HIV infection (see MTB/HIV co-infection)
case-finding campaigns, 473
clinics: re-infection problem, 509
diagnosis, 462–463
DOTS (Directly Observed Therapy. Short Course) strategy, 473, 474, 503, 507, 508
immune reconstitution inflammatory syndrome, 457 (see also immune reconstitution/restoration inflammatory syndrome (IRIS))
lateral infection problem, 464–465, 473
mobile clinics for testing, 473
occult, 521
paradoxical reaction, 523
poverty/adherence to treatment, 512
preventive therapy, 474, 484 fig.
pulmonary, 497
screening pre-antiretroviral therapy, 523, 546
secondary preventive therapy, 466 & fig.
sarmonegative, 516–517
sputum culture, 463
Tugela Ferry district, KwaZulu-Natal
XDR-tuberculosis, 43, 464
U
Uganda, 589
  antiretroviral therapy, 511
  HIV infection decline, 570
  HIV infection/migrant status, 349
  HIV prevention interventions, 294
  sexual risk behaviour, 254
Umkhanyakude (Mtubatuba), KwaZulu-Natal, 437
United States. Centers for Disease Control and Prevention (CDC)
  HIV positive prevention policy (2003), 251
United States. Health and Social Services 2002 (DHSS) guidelines for ART initiation, 542
United States. National Bioethics Advisory Commission (NBAC)
  Ethical and Policy Issues in International Research : Clinical Trials in Developing Countries report (2001), 399–400
V
vaccination, 486
vaccine design, 147–148
  CTL/HLA significance, 151
  T-cell based, 149–150
vaccine trial participants, 106
Vaccinia Ankara (MVA), 150, 270, 275
vaginal candidiasis, 218, 219
varicella zoster virus, 522
Venezuelan Equine Encephalitis Virus, 270
ventilation, 526
Versant HIV-1 RNA 3.0 assay (BDNA), 538
videx (ddI), 546
violence, 300, 318, 325, 338
viral load assays, 110–114
  real time amplification, 113
  in vaccine design, 149–150
virginity
  sociocultural norms, 300, 320
  Virodene dispute, 41
vitamin A, 494, 496, 497–498
  B12, 498
  low serum, 498
vitamin B (pyridoxine), 465
vitamin C, 495, 497–498
vitamin E, 495–498

W
wasting disease, 490–491, 521, 525
  weight loss (wasting syndrome), 53, 362, 462, 481 fig., 489, 490
  Welkom, Free State
  sex worker STI prevention intervention, 353
  Wellconal (dipipanone) ’pinks’, 241
  Western Blot (WB) confirmatory test, 98
  Western Cape province
  antiretroviral therapy provision free, 587
  public sector condom distribution, 189
  Western Province Blood Transfusion Service, 227
  whey protein, 496
  widows, AIDS-access to land/housing, 375
women
  abuse, 168
  cultural values, 295
  drug sharing with children, 516
  empowerment interventions, 302–303
  female condoms, 186, 188–189, 293, 294
  gender inequality, 163–164, 275, 286, 317
  gender status, 514–515
  HIV-wasting syndrome, 491
  imbalance in power, 286
  iron-deficiency anaemia, 497
  patriarchy/white supremacy effect on blacks, 296–297
  pregnancy/HIV combination, 310–311
  risk of HIV infection, 50, 287
  see also femininity; mother-to-child transmission (MTCT); sexual behaviour
women-controlled prevention methods, 268, 275
World Health Organisation (WHO)
  criteria for diagnosis of extrapulmonary pneumonia, 517
  criteria for diagnostic tests at certain prevalence, 104
  Global Fund (see Global Fund against AIDS, Tuberculosis and Malaria)
  Global Plan to Stop Tuberculosis, 474
  guidelines for antiretroviral therapy (2009), 539, 542, 547, 553
  guidelines for antiretroviral therapy for pregnant women (2009), 211
  guidelines for diagnosis of SNTB, 517
  guidelines for use of tests, 104
  palliative care definition, 524
  prequalification process (for medicines), 557
  ‘Protest’ initiative, 508
World Medical Association (WMA). General Assembly
Declaration of Helsinki (see Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects)
World Trade Organisation agreements regarding generic antiretroviral medication, 589

X
XDR-TB epidemic, Tugela Ferry, KwaZulu-Natal, 43, 464

Y
young adults see youth
young men, 306
gender role norms, 317
leisure activities, 319
multiple partnerships, 306
young women, 306
gender role norms/inequalities, 305, 308, 317
interventions preventing infection, 305–306
leisure activities, 319
older partners, 298, 306
sexual coercion, 300, 306

Z
zalcitabine (ddC), 534 fig., 543–544
Zambia
nutritional supplements trial, 497
zidovudine (AZT), 90, 207, 470, 471, 529, 534 fig., 542, 543, 544, 549, 553
regimen 076, 394–398
Zimbabwe
AIDS impact on subsistence farming, 425
HIV infection decline, 570
HIV prevalence, 57 & fig., 298
HIV-positive men, 349
pregnant women/ferritin/viral load, 498
zinc, 494, 497
zoonotic infections, 484
Zuma, Jacob, President
HIV/AIDS policy, 449–453